Navigation Links
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

- First in human clinical data highlight safety profile of BSI-201 in

subjects with advanced solid tumors -

BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.

Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.

The schedule of poster presentations is as follows:

Title: First in Human Phase 1 Study of BSI-201, a Small Molecule

Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with

Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract#: 3577

Title: A Phase 1B Study Evaluating BSI-201 in Combination with

Chemotherapy in Subjects with Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract #: 3579

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the ... and Future" report to their offering. ... This research service on the global ... and provides a snapshot of the key participants in the market. ... provided from 2016 to 2020. The market is expected to grow ...
(Date:1/20/2017)... , VAE, January 20, 2017 ... stark gestiegenen Bedarf an Nothilfe   Die internationale ... Platz für Hilfsgüter zu schaffen   ... und Premierminister der VAE sowie Herrscher von ... der internationalen Stadt der Hilfe (International Humanitarian City IHC) ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
Breaking Medicine Technology:
(Date:1/21/2017)... Santa Barbara, CA (PRWEB) , ... January 21, ... ... through its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events ... enlivening festivities for alumni, family, friends, and community. “Coming Home 2017” will ...
(Date:1/20/2017)... Missoula, MT (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA ... use, saving deck space. Since the lift is mounted on wheels, it can be wheeled ... a lock down kit, to fasten to the deck. "We have transformed the feedback from ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted ... had a successful January ECRM Trade Show in Hilton Head, SC. , Bionic ... it to provide its products to all clients at reasonable prices. At the ECRM ...
(Date:1/20/2017)... Aliso Viejo, California (PRWEB) , ... January 20, 2017 , ... ... and easy to use inside of Final Cut Pro X," said Christina Austin - ... filmed on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and ...
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
Breaking Medicine News(10 mins):